Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma
In: BMC Cancer, Jg. 23 (2023), Heft 1, S. 1-9
Online
academicJournal
Zugriff:
Abstract Introduction COVID-19 particularly impacted patients with co-morbid conditions, including cancer. Patients with melanoma have not been specifically studied in large numbers. Here, we sought to identify factors that associated with COVID-19 severity among patients with melanoma, particularly assessing outcomes of patients on active targeted or immune therapy. Methods Using the COVID-19 and Cancer Consortium (CCC19) registry, we identified 307 patients with melanoma diagnosed with COVID-19. We used multivariable models to assess demographic, cancer-related, and treatment-related factors associated with COVID-19 severity on a 6-level ordinal severity scale. We assessed whether treatment was associated with increased cardiac or pulmonary dysfunction among hospitalized patients and assessed mortality among patients with a history of melanoma compared with other cancer survivors. Results Of 307 patients, 52 received immunotherapy (17%), and 32 targeted therapy (10%) in the previous 3 months. Using multivariable analyses, these treatments were not associated with COVID-19 severity (immunotherapy OR 0.51, 95% CI 0.19 – 1.39; targeted therapy OR 1.89, 95% CI 0.64 – 5.55). Among hospitalized patients, no signals of increased cardiac or pulmonary organ dysfunction, as measured by troponin, brain natriuretic peptide, and oxygenation were noted. Patients with a history of melanoma had similar 90-day mortality compared with other cancer survivors (OR 1.21, 95% CI 0.62 – 2.35). Conclusions Melanoma therapies did not appear to be associated with increased severity of COVID-19 or worsening organ dysfunction. Patients with history of melanoma had similar 90-day survival following COVID-19 compared with other cancer survivors.
Titel: |
Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma
|
---|---|
Autor/in / Beteiligte Person: | Johnson, Douglas B. ; Atkins, Michael B. ; Hennessy, Cassandra ; Wise-Draper, Trisha ; Heilman, Hannah ; Awosika, Joy ; Bakouny, Ziad ; Labaki, Chris ; Renee Maria Saliby ; Hwang, Clara ; Singh, Sunny R. K. ; Balanchivadze, Nino ; Friese, Christopher R. ; Fecher, Leslie A. ; Yoon, James J. ; Hayes-Lattin, Brandon ; Bilen, Mehmet A. ; Castellano, Cecilia A. ; Lyman, Gary H. ; Tachiki, Lisa ; Shah, Sumit A. ; Glover, Michael J. ; Flora, Daniel B. ; Wulff-Burchfield, Elizabeth ; Kasi, Anup ; Abbasi, Saqib H. ; Farmakiotis, Dimitrios ; Viera, Kendra ; Klein, Elizabeth J. ; Weissman, Lisa B. ; Jani, Chinmay ; Puc, Matthew ; Fahey, Catherine C. ; Reuben, Daniel Y. ; Mishra, Sanjay ; Beeghly-Fadiel, Alicia ; French, Benjamin ; Warner, Jeremy L. ; COVID-19 and Cancer Consortium |
Link: | |
Zeitschrift: | BMC Cancer, Jg. 23 (2023), Heft 1, S. 1-9 |
Veröffentlichung: | BMC, 2023 |
Medientyp: | academicJournal |
ISSN: | 1471-2407 (print) |
DOI: | 10.1186/s12885-023-10708-6 |
Schlagwort: |
|
Sonstiges: |
|